FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013094952> ?p ?o ?g. }

• W2013094952 endingPage "421" @default.
• W2013094952 startingPage "416" @default.
• W2013094952 abstract "Aromatase Inhibitors as Adjuvant Therapy Adjuvant hormonal therapy significantly improves disease-free and overall survival in patients with stage I, II, or III breast cancer and hormone receptor–positive tumors.1,2 For some time, 5 years of adjuvant tamoxifen has been the gold standard. However, recent results from studies evaluating the third generation aromatase inhibitors (AIs) as adjuvant therapy in postmenopausal women have challenged the primacy of tamoxifen for this group of patients.3-14 In patients with advanced-stage breast cancer, the third generation nonsteroidal AIs anastrozole and letrozole as well as the steroidal inactivator exemestane have been found superior to megestrol acetate as second-line therapy15-21 and at least equivalent (and possibly superior) to tamoxifen as first-line therapy.21-25 Based on these results, several clinical trials have evaluated or are currently evaluating AIs as adjuvant therapy in postmenopausal patients with early-stage breast cancer. In the adjuvant setting, AIs have demonstrated activity in 3 distinct clinical scenarios. In the first, an AI was compared with tamoxifen as initial adjuvant hormonal therapy in patients with resected operable breast cancer.3-5 The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial demonstrated that 5 years of anastrozole significantly improved disease-free survival (DFS) when compared with 5 years of tamoxifen.3,4 More recently, the BIG (Breast Intergroup) 1-98 trial also demonstrated similar benefit for 5 years of letrozole compared with 5 years of tamoxifen.5 In the second scenario, an AI was compared with tamoxifen in patients who had already received 2-3 years of adjuvant tamoxifen.6-10 In 3 randomized trials (the IES [Intergroup Exemestane Study] trial,6,7 the ABCSG [Austrian Breast and Colorectal Cancer Study Group]–8/ARNO [ArimidexNSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor–Positive Breast Cancer" @default.
• W2013094952 created "2016-06-24" @default.
• W2013094952 creator A5011100408 @default.
• W2013094952 creator A5020711450 @default.
• W2013094952 creator A5027209040 @default.
• W2013094952 creator A5033033849 @default.
• W2013094952 creator A5033411602 @default.
• W2013094952 creator A5055013606 @default.
• W2013094952 creator A5060196610 @default.
• W2013094952 creator A5063504632 @default.
• W2013094952 creator A5073338995 @default.
• W2013094952 creator A5082509731 @default.
• W2013094952 date "2006-12-01" @default.
• W2013094952 modified "2023-09-24" @default.
• W2013094952 title "NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor—Positive Breast Cancer" @default.
• W2013094952 cites W1453600927 @default.
• W2013094952 cites W1531964529 @default.
• W2013094952 cites W1562190372 @default.
• W2013094952 cites W1815807371 @default.
• W2013094952 cites W1839333839 @default.
• W2013094952 cites W1909697168 @default.
• W2013094952 cites W1918073772 @default.
• W2013094952 cites W1932574503 @default.
• W2013094952 cites W1934173384 @default.
• W2013094952 cites W1961026612 @default.
• W2013094952 cites W1991856294 @default.
• W2013094952 cites W1992095316 @default.
• W2013094952 cites W2001589762 @default.
• W2013094952 cites W2096446019 @default.
• W2013094952 cites W2096840197 @default.
• W2013094952 cites W2101881391 @default.
• W2013094952 cites W2103933822 @default.
• W2013094952 cites W2121656289 @default.
• W2013094952 cites W2122095366 @default.
• W2013094952 cites W2124903864 @default.
• W2013094952 cites W2132846837 @default.
• W2013094952 cites W2142739119 @default.
• W2013094952 cites W2153247110 @default.
• W2013094952 cites W2163688875 @default.
• W2013094952 cites W2166631738 @default.
• W2013094952 cites W2171538830 @default.
• W2013094952 cites W2202169216 @default.
• W2013094952 cites W2508460892 @default.
• W2013094952 cites W4230686738 @default.
• W2013094952 cites W4243828894 @default.
• W2013094952 doi "https://doi.org/10.3816/cbc.2006.n.061" @default.
• W2013094952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17239269" @default.
• W2013094952 hasPublicationYear "2006" @default.
• W2013094952 type Work @default.
• W2013094952 sameAs 2013094952 @default.
• W2013094952 citedByCount "37" @default.
• W2013094952 countsByYear W20130949522013 @default.
• W2013094952 countsByYear W20130949522014 @default.
• W2013094952 countsByYear W20130949522015 @default.
• W2013094952 countsByYear W20130949522016 @default.
• W2013094952 countsByYear W20130949522017 @default.
• W2013094952 countsByYear W20130949522018 @default.
• W2013094952 countsByYear W20130949522019 @default.
• W2013094952 countsByYear W20130949522020 @default.
• W2013094952 countsByYear W20130949522021 @default.
• W2013094952 countsByYear W20130949522023 @default.
• W2013094952 crossrefType "journal-article" @default.
• W2013094952 hasAuthorship W2013094952A5011100408 @default.
• W2013094952 hasAuthorship W2013094952A5020711450 @default.
• W2013094952 hasAuthorship W2013094952A5027209040 @default.
• W2013094952 hasAuthorship W2013094952A5033033849 @default.
• W2013094952 hasAuthorship W2013094952A5033411602 @default.
• W2013094952 hasAuthorship W2013094952A5055013606 @default.
• W2013094952 hasAuthorship W2013094952A5060196610 @default.
• W2013094952 hasAuthorship W2013094952A5063504632 @default.
• W2013094952 hasAuthorship W2013094952A5073338995 @default.
• W2013094952 hasAuthorship W2013094952A5082509731 @default.
• W2013094952 hasConcept C121608353 @default.
• W2013094952 hasConcept C126322002 @default.
• W2013094952 hasConcept C142724271 @default.
• W2013094952 hasConcept C143998085 @default.
• W2013094952 hasConcept C204787440 @default.
• W2013094952 hasConcept C27081682 @default.
• W2013094952 hasConcept C2776166826 @default.
• W2013094952 hasConcept C2778311097 @default.
• W2013094952 hasConcept C2778504769 @default.
• W2013094952 hasConcept C2778812593 @default.
• W2013094952 hasConcept C29456083 @default.
• W2013094952 hasConcept C530470458 @default.
• W2013094952 hasConcept C535046627 @default.
• W2013094952 hasConcept C71924100 @default.
• W2013094952 hasConceptScore W2013094952C121608353 @default.
• W2013094952 hasConceptScore W2013094952C126322002 @default.
• W2013094952 hasConceptScore W2013094952C142724271 @default.
• W2013094952 hasConceptScore W2013094952C143998085 @default.
• W2013094952 hasConceptScore W2013094952C204787440 @default.
• W2013094952 hasConceptScore W2013094952C27081682 @default.
• W2013094952 hasConceptScore W2013094952C2776166826 @default.
• W2013094952 hasConceptScore W2013094952C2778311097 @default.
• W2013094952 hasConceptScore W2013094952C2778504769 @default.
• W2013094952 hasConceptScore W2013094952C2778812593 @default.
• W2013094952 hasConceptScore W2013094952C29456083 @default.
• W2013094952 hasConceptScore W2013094952C530470458 @default.

• next